Loss of function in the deubiquitinase USP9X appears to be associated with resistance to tamoxifen in patients with ER alpha-positive breast cancer, according to study findings.
The results suggest this gene signature may help predict how patients will respond to the drug, researchers wrote.
Full Story »
Personalize your page!
Register for Healio to get content tailored to your specialty and areas of interest.
It’s FREE and only takes one minute.